Ovid Therapeutics Q2 net loss $4.7M, cash $38.3M; receives Nasdaq extension to Feb 2026

Ovid Therapeutics Inc.

Net loss of $4.7M ($0.06 EPS) vs net income of $8.5M ($0.12 EPS) in Q2 2024.
Revenue from royalty agreements $6.3M (vs $169K), including $7.0M ganaxolone royalty monetization with Immedica.
Cash $38.3M, expected to fund operations into early 2H 2026.
OV329 Phase 1 topline safety/biomarker results anticipated Q3 2025.
Company transferred to Nasdaq Capital Market with extended bid price compliance deadline to Feb 9, 2026.

item 2.02item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.